Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (17221)	3/15/1999 9:21:00 AM
From: Jane4IceCream	Read Replies (4) \| Respond to of 90042

IMCL: I was rather shocked it didnt do the GERN or maybe part of the ENMD thing. I had bought a little chunk of IMCL at 10 7/8 and held it too long eventually selling it at 14. Jane

To: QuietWon who wrote (17221)	3/15/1999 9:29:00 AM
From: Toni Wheeler	Respond to of 90042

QW...speaking of biotechs and cancer...did you see this?: CEL-SCI Announces Start of Prostate Cancer Study VIENNA, Va., March 15 /PRNewswire/ -- Thomas Jefferson University of Philadelphia, Pennsylvania, CEL-SCI CORPORATION (Amex: HIV; Berlin: LSR) and Drs. Michael Mastrangelo and Leonard Gomella of Thomas Jefferson University Hospital have started a second prostate cancer study with Multikine(TM), an immune boosting product developed by CEL-SCI Corporation. The study will test Multikine in escalating doses as a pre-treatment before prostatectomy (surgical removal of the prostate) in up to 20 previously untreated, advanced prostate cancer patients. Drs. Mastrangelo and Gomella had initially tested Multikine in previously treated, advanced prostate cancer patients and shown it to be safe and to induce inflammatory responses against the tumor. In another study, presented in 1998, in which Multikine was administered prior to surgery to 10 head and neck cancer patients, good tumor responses were observed after only 2 weeks of treatment, including one complete clinical tumor response. It is the hope of the treating physicians that the administration of Multikine prior to prostatectomy will show equally beneficial results. Dr. Michael Mastrangelo, Professor of Medicine at Thomas Jefferson University Hospital, stated, "We hypothesize that Multikine treatment prior to surgery or radiation (neo-adjuvant therapy) will induce an immune response against the tumor which will sharply reduce the number of failures (tumor recurrences)." Multikine is a natural mixture of human immune system regulators called cytokines. It contains Interlcukin-2 and other cytokines, several of which are being investigated individually as potential cancer treatments. The product is in clinical trials in the U.S. and Canada and Israel for the treatment of head and neck cancer and HIV. Two phase II studies involving a total of 60 patients are expected to start soon in Hungary, Poland and the Czech Republic. CEL-SCI Corporation is developing novel immunotherapies and vaccines for cancer, AIDS and other major diseases. CEL-SCI press releases are available through Company News On-Call by fax, 800-758-5804, ext. 445563, or at cel-sci.com on the Internet. When used in this report, the words "intends," "believes," anticipated," and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1998. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. SOURCE CEL-SCI Corporation CO: CEL-SCI Corporation ST: Virginia IN: MTC SU: PDT 03/15/99 08:30 EST prnewswire.com